News

Biological material for biomarker research in spondyloarthritis: Mapping the availability in European rheumatology registries Click here to access full article

Comparing DAPSA, DAPSA28, and DAS28-CRP in PatientsWith Psoriatic Arthritis Initiating a First Tumor NecrosisFactor Inhibitor Across Nine European Countries Click here to access full article

Effectiveness of secukinumab in radiographic and non-radiographic axial spondyloarthritis: a European routine-care observational study Click here to access full article

Sex differences in patient-reported outcome measures and the association with clinical factors in axial spondyloarthritis patients treated with tumour necrosis factor inhibitors Click here to access full article

Cut-Offs for Disease Activity States in Axial Spondyloarthritis With Ankylosing Spondylitis Disease Activity Score (ASDAS) Based on C-Reactive Protein and ASDAS Based on Erythrocyte Sedimentation Rate: Are They Interchangeable? Click here to access full article

Enthesitis in a European registry-based cohort of patients with psoriatic arthritis treated with tumour necrosis factor inhibitors: clinical burden, patient-reported outcomes, and treatment response Click here to access full article

Drug effectiveness of 2nd and 3rd TNF inhibitors in psoriatic arthritis – relationship with the reason for withdrawal from the previous treatment Click here to access full article

Patient-reported outcomes and PRO remission rates in 12,262 biologic-naïve patients with psoriatic arthritis Click here to access full article This publication is featured in Editor's Picks Spotlight by the Journal of Rheumatology, see the interview with Lykke Ørnbjerg here:

Sex Differences in the Effectiveness of First-Line Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis: Results From the European Spondyloarthritis Research Collaboration Network Click here to access full article

Patient-reported outcomes in axial spondyloarthritis and psoriatic arthritis patients treated with secukinumab for 24 months in daily clinical practice Click here to access full article

Sex differences in the effectiveness of first-line tumour necrosis factor inhibitors in axial spondyloarthritis: results from the EuroSpA Research Collaboration Network Click here to access full article

Commonalities and differences in set-up and data collection across European spondyloarthritis registries — results from the EuroSpA collaboration Click here to access full article

Second and third TNF inhibitors in European patients with axial spondyloarthritis: effectiveness and impact of the reason for switching Click here to access full article Plain language video presentation: Plain language summary EuroSpA publication 1.4, interview with Louise Linde Plain language summary text: [...]

Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe Click here to access full article Plain language summary (in danish) Featured in Magasinet om Rygsøjlegigt, May 2024

Predictors of DAPSA28 remission in patients with psoriatic arthritis initiating a first TNF inhibitor: results from 13 European registries Click here to access full article Plain language video presentation: Plain language summary EuroSpA publication 4.1, interview with Louise Linde Plain language summary [...]

One-Third of European Patients with Axial Spondyloarthritis Reach Pain Remission With Routine Care Tumor Necrosis Factor Inhibitor Treatment Click here to access full article Plain language video presentation: Plain language summary EuroSpA publication 2.2, interview with Lykke Ørnbjerg Plain language summary text: [...]

Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: Data from the EuroSpA collaboration Click here to access full article Plain language summary: “Age, sex, smoking status and other common factors may predict which patients with axial spondyloarthritis achieve inactive disease when treated with TNF [...]

European bio-naïve spondyloarthritis patients initiating TNF inhibitor: time trends in baseline characteristics, treatment retention and response Click here to access full article

The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondylarthritis Click here to access full article

Real-World Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries Click here to access full article